Objectives: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. Platelet activation and aggregation are central processes in the pathophysiology of atherothrombosis. Mean platelet volume (MPV), a determinant of platelet activation, is a newly-emerging risk factor for atherothrombosis. Therefore, we have investigated the possible association between OSAS and MPV. Study design: We selected 30 mild, 32 moderate, and 31 severe OSAS patients and 31 healthy control subjects matched for age, sex, and body mass index. MPV was measured using an automated blood cell counter. Results: The MPV levels were significantly higher in the severe OSA group than in the control group (8.6±1.1 vs. 7.8±0.7 fl, p=0.03). There were no significant differences in respect to MPV between controls and patients with mild and moderate OSA (7.8±0.7 vs. 8.3±1.2 fl, p=0.2; 7.8±0.7 vs. 8.4±1.3 fl, p=0.08) and between patients with mild, moderate, and severe OSA (8.3±1.2 vs. 8.4±1.3 vs. 8.6±1.1 fl, p=0.9). Significant correlations were seen between MPV and apneahypopnea index (r=0.347, p≤0.001), minimal oxygen saturation (r=-0.224, p=0.03), and the percentage of recording time spent at a oxygen saturation less than 90% (r=0.240, p=0.02). Conclusion: Our results suggest that OSAS patients tend to have relatively increased platelet activation andatherothrombotic risk.
bstructive sleep apnea syndrome (OSAS) is characterized by repetitive apnea or hypopnea due to narrowing of the upper airways during sleep. It is a common disorder of middle-aged adults, affecting 4% of men and 2% of women. [1] OSAS is an independent risk factor for cardiac mortality and morbidity. In patients without underlying cardiovascular disease, hypertension, coronary artery disease, stroke, and heart failure are shown to be associated with OSAS. [2, 3] Recent studies have indicated that OSAS is associated with multiple causal factors of endothelial damage and atherosclerosis due to systemic inflammation, oxidative stress, and increased levels of soluble adhesion molecules and coagulation factors. Furthermore, all of these causal factors have been reported to significantly decrease after treatment of OSAS with continuous positive airway pressure. [4, 5] Increased platelet activation plays an important role in the development of cardiovascular complications. [6] Several studies have reported increased platelet activation and aggregation in patients with OSAS. [7] [8] [9] [10] Increased platelet activity is associated with increased platelet volume. Large platelets that contain denser granules are metabolically and enzymatically more active than small platelets and have higher thrombotic potential. [10] [11] [12] [13] Mean platelet volume (MPV) is an indicator of platelet activation and has an important role in the pathophysiology of cardiovascular diseases [6, 14] such as hypertension, diabetes mellitus, hypercholesterolemia, and acute myocardial infarction. [15] This study investigated the MPV levels in OSAS patients without hypertension, smoking history, diabetes, hyperlipidemia, and any cardiovascular disease, and assessed whether there was any correlation between MPV and severity of disease.
PATIENTS AND METHODS

Patients
Patients between ages 30 and 60 diagnosed with OSAS who were examined in the Department of Chest Diseases outpatient clinic between March 2009 and October 2010 were included in this study. Polysomnographies at the sleep laboratory were conducted prior to inclusion in this study. Patients were examined in three groups according to the severity of their OSAS determined by the apnea-hypopnea index (AHI): 30 in the mild OSAS group (AHI=5-15), 32 in the moderate group (AHI=16-30), and 31 in the severe group (AHI >30). As a control, 31 asymptomatic, healthy individuals between ages 30 and 60 who were seen in the Department of Cardiology outpatient clinic were chosen. This group included patients suitable for the study from the perspective of cardiac anatomy and functions, those with no night snoring or day-time sleepiness, who scored less than 10 in the Epworth sleepiness scale, and had low risk of OSAS in the Berlin survey form evaluation. [16] [17] [18] The study was approved by the local Ethics Committee. Informed consents were taken from every individual included in the study. All patients underwent a detailed examination of the cardiovascular system.
Criteria for exclusion
Exclusion criteria were as follows: (1) impaired cardiopulmonary function, defined as the occurrence of respiratory failure, pulmonary infection or congestive heart failure; (2) coronary artery disease, defined as having a typical angina pectoris, history of a prior myocardial infarction, or the presence of a positive stress test or positive coronary angiographic findings; (3) valvular disease, atrial fibrillation or congenital heart disease; (4) hypertension (hypertension was considered to be present if the systolic pressure was >140 mmHg and/or diastolic pressure was >90 mmHg after averaging three separate blood pressure measurements taken at 10 min intervals, as well as in patients receiving antihypertensive treatment), [19] diabetes mellitus (diabetes mellitus was defined as a fasting blood glucose level >126 mg/dl or current use of a diet or medication to lower blood glucose and/or HbA1c >6.5%), dyslipidemia (LDL cholesterol >160 mg/dl, total cholesterol >240 mg/dl, triglyceride >250 mg/dl), or using antihypertensives, antidiabetics, or lipid-lowering treatment; (5) chronic alcoholism and smoking; (6) malignancy, hyperthyroidism, and hypothyroidism; (7) history of prolonged use of non-steroid anti-inflammatory drugs or anticoagulants; and (8) renal and liver insufficiency. [20]
Polysomnography
Biochemical measurements
Biochemical parameters were obtained from venous blood samples drawn after a 12 hour fasting period. MPV was measured in a blood sample collected in dipotassium EDTA tubes. An automatic blood counter was used for whole blood counts. MPV was measured within 30 minutes after sampling to prevent EDTAinduced platelet swelling.
Statistical analysis
All data was analyzed with "MedCalc 11.0.4" and "SPSS 15.0 for Windows" software. Numerical variables were defined as mean ± standart deviation; categorical variables were defined as percentiles. In a comparision of three or more groups, if the variables fit the normal distribution, one-way analysis of variance (ANOVA) was used; if not, the Kruskal-Wallis test was used. In comparision of the categorical variables, the multiple comparision chi-square test was used. In post-hoc analysis, Tukey's test was used after one-way ANOVA, and the Mann-Whitney U-test was used after Kruskal-Wallis. The KolmogorovSmirnov test was used for normality of the distribution. Spearman correlation analysis was performed for determination of correlation. All hypotheses were established as two-way, and alpha critical value was accepted as 0.05. 59.4±15.9 in the severe OSAS group. The difference in AHI, SaO 2 min, and SaO 2 <90% (TST%) between groups was statistically significant ( Table 1) .
The MPV values were markedly higher in patients with severe OSAS than in the control group (8.6±1.1 vs. 7.8±0.7 fl, p=0.03) (Fig. 1 ). There were no significant differences between controls and patients with mild and moderate OSAS (7.8±0.7 vs. 8 (Fig. 1) . Additionally, correlation of MPV with parameters of sleep was noted. MPV correlated with AHI (r=0.347, p=<0.001) (Fig. 2) , SaO 2 min (r=-0.224, p=0.03), and TST% (r=0.240, p=0.02).
DISCUSSION
In this study, we have demonstrated significant association between MPV and severity of disease in patients with OSAS.
Obstructive sleep apnea syndrome is a systemic disorder that leads to cardiovascular complications. Recent studies show that OSAS is not a simple respiratory abnormality during sleep; the systemic inflammatory response generated by OSAS can be associated with cardiovascular diseases and increased
RESULTS
There were no differences among groups in age, sex, BMI, systolic and diastolic blood pressures, or in laboratory parameters: fasting blood glucose, HbA1c, seurm lipid parameters, hemoglobin, hematocrite, and platelet count ( Table 1 atherothrombotic processes. [21, 22] Mean platelet volume is arousing increasing interest as a new, independent cardiovascular risk factor. [15, 23] Increased levels of MPV have been shown in hypertension, hypercholesterolemia, diabetes mellitus, obesity, metabolic syndrome, acute myocardial infarction, and acute ischemic stroke. [15] In the study by Varol et al., [10] levels of MPV were significantly greater in patients with severe OSAS versus patients in the control group and patients with mild to moderate OSAS; however, this study did not exclude hypertension, hypercholesterolemia, and smoking, which could lead elevated MPV. Nena et al. [24] reported that MPV levels in severe OSAS patients were significantly higher than in control and mild to moderate OSAS. The study did not exclude cardiac or lung disease, chronic renal or hepatic disease, hypertension, hypercholesterolemia, or smoking. Our study excluded conditions increasing MPV, such as cardiovascular disease, hypertension, hypercholesterolemia, and smoking; like Nena et al., the new, more sensitive diagnostic criteria incorporating HbA1c was used to exclude diabetes. [24] [25] [26] Our results indicate that patients with severe OSAS have significantly higher MPV values versus control and mild to moderate OSAS, similar to the studies by Varol et al. and Nena et al. [10, 24] Enhanced coagulability, possibly mediated by increased sympathetic neural activation, may explain the meaningful relationship between OSAS and cardiovascular disease. The circadian distribution of cardiovascular and vascular events strongly suggests an interaction between sleep, arousal, and acute thrombosis. Myocardial infarction and sudden death exhibit a peak occurrence between 6 a.m. and 11 a.m. Platelets play a key role in ischemic cardiovascular disease and increases in platelet aggregability and activation have been demonstrated in patients with OSAS. [27] Minoguchi et al. [9] found that platelet activation was significantly higher in patients with moderate to severe OSAS than in patients with mild OSAS or control subjects. Oga et al. [28] demonstrated that ADP-induced platelet aggregability was significantly increased in patients with moderate to severe OSAS compared to patients with mild to no OSAS. In this study, increased MPV values are seen only in patients with severe OSAS, which agrees with the studies cited above.
The exact mechanism of platelet activation in patients with OSAS is not clear. Three main pathways may be implicated. First, augmented sympathetic activity increases concentrations of epinephrine and norepinephrine as a result of hypoxemia and repetitive arousals from sleep. [29, 30] Platelet activation by catecholamines is dose-dependent. [31, 32] Second, acute and chronic intermittent hypoxia can cause platelet activation directly. [33, 34] Third, chronic inflammation is symptomatic of OSAS and leads to increased secretion of interleukin-6 (IL-6) and other pro-inflammatory cytokines. Interleukin-3 and IL-6 influence megakaryocyte ploidy and can lead to the production of more reactive and larger platelets. Therefore, elevated IL-6 levels in patients with OSAS can cause an increase in MPV values by stimulating the megakaryocyte ploidy. [5, 35, 36] According to Oga et al., [28] in OSAS patients, CPAP therapy may confer some cardioprotective effects through the reduction of platelet activation. They found that ADP-induced platelet aggregability was significantly increased in patients with moderate to severe OSAS compared to patients with mild to no OSAS, and that CPAP treatment improved platelet aggregability at 90 days. Varol et al. [23] found that six months of CPAP therapy caused significant reductions in MPV values in patients with severe OSAS.
Platelet volume is mainly determined in the bone marrow, and large platelets are caused by a reduced fragmentation of megakaryocytes. MPV has been shown to inversely correlate with the total platelet count, which could suggest the consumption of small platelets and a compensatory production of larger reticulated platelets. [10, 15] In our study, there was an inverse relationship between platelet count and MPV. Platelet count tended to decrease from the control group to the severe OSAS group, similar to the findings of Varol et al. [10] However, it could not reach statistical significance.
Our study has some limitations including a small sample size and the use of Epworth's method and the Berlin scale rather than AHI in the selection of control individuals. However, in daily clinical practice, those methods are used for the selection of appropriate patients for the polysomnography test. In addition, previous reports have demonstrated the correlation of the Epworth Sleepiness Scale with the AHI. [37] Hypertensive patients were excluded from our study; there-fore, we were unable to assess the effects of possible increased blood pressure during sleeping which could be induced by apnea and hypopnea episodes.
Conclusion
We found that serum MPV values of patients with severe OSAS were significantly higher than those of the control group, and that MPV correlated with AHI. Our results suggest that patients with severe OSAS, without other cardiovascular risk factors, tend to have an increased platelet activation. Increased platelet activity could contribute to an increased atherothrombotic risk in patients with OSAS. Early diagnosis and CPAP therapy may confer some cardioprotective effects through the reduction of platelet activation.
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